NEW YORK, July 12 (GenomeWeb News) - Caliper Life Sciences has granted Agilent Technologies a non-exclusive license to use a "majority" of Caliper's microfluidics patent estate to develop clinical diagnostic applications on several Agilent instrument platforms, the companies said today.
Specifically, Agilent will incorporate the LabChip microfluidics technology into its 2100 Bioanalyzer, 5100 Automated Lab-on-a-Chip, and future instrument platforms.
Separately, the companies said that Agilent will use Caliper as its exclusive supplier of planar LabChip products for the 2100 Bioanalyzer and future products for the next five years.
Under the terms of the agreement, Agilent will pay an upfront undisclosed licensing fee to Caliper, as well as royalties on future sales of diagnostic LabChip products. Additional financial terms of the agreement were not disclosed.